GW Pharmaceuticals is set to file its cannabis-derived drug with U.S. regulators imminently, following publication of detailed data on its success in fighting severe childhood epilepsy.
Tag Archives: Lennox-Gastaut Syndrome
LONDON, March 29, 2017 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to GW’s investigational product Epidiolex®.
A Duke doctor has refused to continue seeing a nine-year-old North Carolina girl because her family gives her cannabidiol oil to cope with a rare illnes. The nine-year-old, Mia Morley, has a medical condition called Lennox Gastaut Syndrome. Her father, Dylan Morley, said Dr. Muhammad Mikati’s decision was based upon the federal status of CBD oil, which is not FDA approved.
LONDON, Dec. 5, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced additional positive Epidiolex® (cannabidiol or CBD) Phase 3 data in poster presentations at the 70th Annual Meeting of the American Epilepsy Society.
On Sept. 26, 2016, GW Pharmaceuticals (Nasdaq:GWPH), a biopharma company with two promising cannabis-based medications, announced positive results for its third study in the United States on the efficacy of Epidiolex, its experimental CBD-based drug, in treating seizures associated with Lennox-Gastaut syndrome.
An experimental cannabis-derived drug has successfully treated children with severe epilepsy in a third late-stage clinical trial, sending shares in Britain’s GW Pharmaceuticals to a record high on Monday.
GW Pharmaceuticals (NASDAQ:GWPH) could be on its way to eventually winning the first U.S. approval for a marijuana-based prescription drug.
PHOENIX, May 24, 2016 /Weed Wire/ — Insys Therapeutics, Inc. (NASDAQ: INSY) (“Insys” or “the Company”) today announced that it has successfully completed its Phase 1/Phase 2 safety and pharmacokinetic (PK) study in pediatric subjects with treatment-resistant epilepsy.